A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate‐to‐severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO‐BIO‐REAL)

BACKGROUND: Anti‐tumour necrosis factor (TNF) and anti‐interleukin (IL)‐12/23 biologics revolutionized plaque psoriasis treatment by enabling ≥75% improvement in the Psoriasis Area and Severity Index (PASI 75) in clinical trials. Modern biologics are now reported to achieve PASI 100 (complete skin c...

Descripción completa

Detalles Bibliográficos
Autores principales: Seneschal, J., Lacour, J.‐P., Bewley, A., Faurby, M., Paul, C., Pellacani, G., De Simone, C., Horne, L., Sohrt, A., Augustin, M., Hammond, E., Reich, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Psoriasis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818467/
https://www.ncbi.nlm.nih.gov/pubmed/32364296
http://dx.doi.org/10.1111/jdv.16568

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818467/
https://www.ncbi.nlm.nih.gov/pubmed/32364296
http://dx.doi.org/10.1111/jdv.16568

Ejemplares similares